| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Candel Therapeutics, Inc.
13D/A
CADL · 137404109
|
7.9% |
3/18/2026
Event 12/16/2024
|
||||
| Paul B Manning | 7.9% | |||||
| The Paul B. Manning Revocable Trust dated May 10, 2000 | 3.8% | |||||
| BKB Growth Investments, LLC | 1.8% | |||||
|
Verrica Pharmaceuticals Inc.
13D/A
VRCA · 92511W207
|
49.9% |
11/28/2025
Event 11/25/2025
|
||||
| Paul B Manning | 49.9% | |||||
| PBM Capital Investments, LLC | 0.2% | |||||
| BKB Growth Investments, LLC | 20.9% | |||||
|
Taysha Gene Therapies, Inc.
13D/A
TSHA · 877619106
|
9.8% |
6/3/2025
Event 5/30/2025
|
||||
| Paul B Manning | 9.8% | |||||
| The Paul B. Manning Revocable Trust dated May 10, 2000 | 5.6% | |||||
| The PBM 2023 Grantor Retained Annuity Trust | 1.5% | |||||
| The PBM 2025 Grantor Retained Annuity Trust | 1.5% | |||||
| BKB Growth Investments, LLC | 1.1% | |||||
| BKB G2 Investments, LLC | 0% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Liquidia Corp
13G/A
LQDA · 53635D202
|
6.5% |
8/14/2026
Event 6/30/2026
|
||||
| Paul B Manning | 6.5% | |||||
| PD Joint Holdings, LLC Series 2016-A | 0.2% | |||||
| BKB Growth Investments, LLC | 0.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.